"A frontier without an ecosystem is not stable." $TAO must continue strengthening the ecosystem of subnets: vision, DeSci, real estate, compute, storage, LLM, etc. etc.. the breakout will happen.

From Anthropic/US gov saga, let's go one step further, to vision. Imagine a future where one centralized entity controls World's cameras: surveillance concentration, gatekeeping, monopolistic pricing, hidden bias, national dependence, etc. This is why we need Bittensor SN44 $TAO.

Sooner or later centralized big pharma will lobby the bureaucrats in Washington to ban or only allow "certain few" companies the ability to do drug research and discovery. This is why we need $TAO, this is why we need @metanova_labs.

It's $TAO or NEVER

Score is positioning SN44 as a vision model factory. "The pipeline behind it is the story." That's a much larger opportunity. SN44 is the place companies go when they need a custom vision model running local. "distillation is not a one-off trick ... it is a production line." $TAO

"65x increase in molecular search speed compared to standard Thompson sampling methods." LET'S GO @metanova_labs 🚀 $TAO

"the bank of bittensor"? interesting... $TAO

Are IPOs just rich people getting the opportunity to sell pre-mined tokens to retail at high valuations? $SPCX

The only Bittensor SN with a solid network, a top notch product, and a very strong company rapidly shipping: $TAO SN44. Considering locking my stake.

Every and all vision AI will go through SN44. $TAO

"native payments and permissionless access for private companies, agents, and all builders" of vision AI being made possible by $TAO SN44.

Double announcement day for Bittensor's best subnet: 1) expansion into North America, the world's largest AI market, furthering SN44 adoption and 2) conviction locking ONE MILLION dollars of owner alpha. LET'S GO $TAO 🚀

Well done team. $TAO SN44 👏🏽🚀

the solution is @bittensor $TAO

Real world deployment initiated $TAO SN44.

$TAO holders. This one is personal. I live with an autoimmune disease. I know what the standard of care looks like. I know what corticosteroids do to your body when you have to rely on them for years. So when @metanova_labs, SN68, announced its new IL-6 target, I paid attention and locked in to what they are doing. Autoimmune disease affects roughly 50 million Americans and around 8% of the global population. Lupus. Rheumatoid arthritis. Crohn’s. MS. Psoriasis. Hashimoto’s. For many patients, long-term steroid use is still the fallback. The side effects are so brutal. Osteoporosis. Cataracts. Glaucoma. Metabolic damage. Adrenal suppression. Weight gain. Mood instability. IL-6 is one of the major inflammatory signals in the body. If you can target it cleanly, you can potentially treat inflammation without destroying everything else around it. That is why IL-6 inhibitors are already a multi-billion dollar market. Actemra. Kevzara. Treatments that can run tens of thousands per patient per year. Now, NOVA is bringing that into Bittensor. Their last nanobody target was PD-L1 for cancer immunotherapy. They received 8,446 unique nanobody submissions from an open decentralized competition. Now, they are moving to IL-6 in partnership with Yalotein, with top submissions eligible for wet lab validation. That is the important part. This is not just AI generating molecules for a dashboard. This is a decentralized virtual screening flowing toward real biologics development. And if it wasn't for biologics, my quality of life would be so different now! NOVA is also making the chemical search competition more exploration focused. Molecules that are too chemically similar will be rejected. That matters because in drug discovery, making 1,000 versions of the same idea is easy. Finding genuinely different scaffolds that actually work is the hard part. That is where real breakthroughs come from. This is why NOVA is different from most AI drug discovery. NOVA is hundreds of miners competing in parallel, paid in $TAO, ranked by results, and pushing the best candidates toward wet lab testing. Cancer, on the one hand. Inflammation on the next. What I am watching now: How many IL-6 submissions come in compared to the 8,446 from PD-L1. Whether the new exploration rules increase true chemical diversity. Most importantly, what happens in wet lab validation with Yalotein. Because that is where decentralized AI either proves itself in physical reality or it does not. The people who need better autoimmune treatments are not thinking about crypto. They are in waiting rooms or emergency rooms. They are trying to work through pain. They are choosing between rent and the medication. They are hoping for something better, period. If decentralized incentive driven discovery can shave years off the timeline or help lower the cost of better therapies, the impact is not just measured in token price. It is measured in lives and quality of life itself. That is why I care about this network. It's not just a chart. The work. NOVA is one subnet. There are many more. Each one is writing its own version of this incredible mission while the market argues about everything else. I will be watching IL-6 closely. Personally and otherwise. $TAO

Guess what? @bittensor doesn't have an HR team to begin with. $TAO

If you just got laid off from Meta and you build in the field of vision AI or AI powered medicine discovery, look into @webuildscore and @metanova_labs. $TAO

I have an autoimmune condition and can totally relate. I can't be more proud to stake to @metanova_labs $TAO SN68. Imagine if together we fund discoveries of some amazing medications to improve the lives of many millions of people. 👇🏾